Healthcare provider profile · identity verified

Patricia Hammel, MD

Internal Medicine · HYANNIS, MA · NPI 1467403543

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	276	79
Levothyroxine Sodium	Levothyroxine Sodium	209	58
Lisinopril	Lisinopril	206	59
Omeprazole	Omeprazole	153	45
Amlodipine Besylate	Amlodipine Besylate	137	46
Gabapentin	Gabapentin	135	27
Losartan Potassium	Losartan Potassium	135	38
Metformin Hcl	Metformin Hcl	110	23
Hydrochlorothiazide	Hydrochlorothiazide	97	28
Simvastatin	Simvastatin	96	33
Metoprolol Succinate	Metoprolol Succinate	89	30
Pantoprazole Sodium	Pantoprazole Sodium	73	22
Rosuvastatin Calcium	Rosuvastatin Calcium	73	19
Zolpidem Tartrate	Zolpidem Tartrate	69	20
Lorazepam	Lorazepam	63	20
Citalopram Hbr	Citalopram Hydrobromide	62	15
Furosemide	Furosemide	62	22
Albuterol Sulfate Hfa	Albuterol Sulfate	50	14
Tamsulosin Hcl	Tamsulosin Hcl	43	11
Tramadol Hcl	Tramadol Hcl	43	16
Trazodone Hcl	Trazodone Hcl	42	13
Prednisone	Prednisone	41	29
Allopurinol	Allopurinol	38	12
Escitalopram Oxalate	Escitalopram Oxalate	38	15
Atenolol	Atenolol	37	suppressed
Famotidine	Famotidine	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	15
Azithromycin	Azithromycin	34	34
Pravastatin Sodium	Pravastatin Sodium	33	11
Xarelto	Rivaroxaban	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Lovastatin	Lovastatin	29	suppressed
Ibuprofen	Ibuprofen	26	suppressed
Sertraline Hcl	Sertraline Hcl	25	suppressed
Synthroid	Levothyroxine Sodium	25	suppressed
Nystatin	Nystatin	24	11
Valacyclovir	Valacyclovir Hcl	24	11
Carvedilol	Carvedilol	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Doxepin Hcl	Doxepin Hcl	21	suppressed
Ozempic	Semaglutide	21	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Amiodarone Hcl	Amiodarone Hcl	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Estradiol (Once Weekly)	Estradiol	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Mono-Linyah	Norgestimate-Ethinyl Estradiol	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Clonazepam	Clonazepam	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Cephalexin	Cephalexin	15	14
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Eliquis	Apixaban	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Amoxicillin	Amoxicillin	14	14
Aripiprazole	Aripiprazole	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Torsemide	Torsemide	14	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Metronidazole	Metronidazole	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Risperidone	Risperidone	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Naproxen	Naproxen	12	suppressed
Valsartan	Valsartan	12	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error